When are IP holders liable for enforcing a later invalidated IP right?
On behalf of our entire IP team, we first and foremost would like to wish you the very best for the New Year, and invite you to our first IP Update of 2023.
As many of you will know, this is a ‘hot’ topic. In 2019, the CJEU delivered its judgment in Bayer v Gedeon Richter (C-688/17), which addressed this question regarding the loss suffered from a provisional injunction based on a subsequently invalidated patent. On 11 October 2022, the Brussels Court of Appeal delivered its judgment in Mylan v Novartis applying the CJEU’s principles to a case where the patentee had enforced a provisional injunction based on the Belgian tier of a subsequently invalidated European patent. The day before, on 10 October 2022, the Finnish Markinnaoikeus had referred another question for a preliminary ruling to the CJEU relating to a subsequently invalidated SPC (C-473/22).
Christophe and Kirian will focus on these two judgments and the pending referral in the broader context of earlier case law and explain what their outcomes could mean for your business. They will answer questions that include:
- Is an IP holder automatically liable for enforcing a provisional injunction based on a later invalidated IP right?
- Is the answer different if it concerns a first instance provisional injunction that is later overturned on appeal?
- Under what circumstances would an IP holder be considered to have ‘abused’ its right to enforce the later invalidated right?
This webinar will be in English and has been accredited with 1 point by the IBJ/IJE.
We look forward to virtually meeting you soon!
WEBINAR VIDEO | Geographical Indications for craft and industrial products: navigating the new EU legal framework
During this webinar, Olivier Vrins and Bart Junior Bollen walk you through the new EU Regulation on GIs for craft and industrial products.Read on
For the first time, the CJEU has been asked to clarify the temporal applicability of the right to “appropriate and proportionate remuneration” laid down in Article 18 of Directive (EU) 2019/790 on copyright and related rights in the Digital Single Market (“DSM Directive”).Read on
Despite many initiatives by the (former) Minister of Health, the uptake of biosimilars in Belgium has remained rather low. In this blog, we summarise the new rules, which apply since 2 October 2023.Read on